Baloghia alternifolia
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1263570 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Melaleuca alternifolia Raw sequence reads
| PRJNA1031371 | ENA
Project description:Wenchengia alternifolia Genome sequencing and assembly
| PRJNA715901 | ENA
Project description:Melaleuca alternifolia isolate:SCU01 Genome sequencing and assembly
| PRJNA702189 | ENA
Project description:Nanopore and Illumina sequencing, and chloroplast genome assembly of Verbesina alternifolia (Asteraceae)
| PRJEB74555 | ENA
Project description:Buddleja alternifolia isolate:LA-IB0 Genome sequencing and assembly
| PRJNA577174 | ENA
Project description:Genome-Wide Analysis of MYB Gene Family in medicinal tea tree Melaleuca alternifolia (Maiden & Betche) Cheel and Identification of Members Regulating Terpene Biosynthesis
| PRJNA1056311 | ENA
Project description:Essential oils (EO) are aromatic compounds from the plant secondary metabolism. Melaleuca alternifolia EO is well known for its medicinal properties and promising use as an antimicrobial agent. Pythiosis is a difficult-to-treat and emerging disease caused by the oomycete Pythium insidiosum. This study evaluated a nanoemulsion formulation of M. alternifolia (NEMA) in topical and intralesional application to treat experimental pythiosis. Dermal toxicity tests were performed on M. alternifolia EO in Wistar rats. Pythiosis was reproduced in rabbits (n = 9) that were divided into groups: group 1 (control), cutaneous lesions with daily topical application of a non-ionizable gel-based formulation and intralesional application of sterile distilled water every 48 h; group 2 (topical formulation), lesions treated daily with topical application of a non-ionizable gel-based formulation containing 5 mg/ml of NEMA; and group 3 (intralesional formulation), lesions treated with NEMA at 5 mg/ml in aqueous solution applied intralesionally/48 h. The animals were treated for 45 days, and the subcutaneous lesion areas were measured every 5 days. M. alternifolia EO showed no dermal toxicity. The lesion areas treated with intralesional NEMA reduced at the end of treatment, differing from groups 1 and 2 (P < 0.05). In the topically treated group, the lesion areas did not differ from the control group, although the number of hyphae significantly reduced (P < 0.05). Under the experimental conditions of this study, the NEMA formulations presented a favorable safety profile. However, further studies are required to evaluate if this safety applies to higher concentrations of NEMA and to validate its use in clinical pythiosis.
| S-EPMC9151964 | biostudies-literature